Taysha Gene Therapies (TSHA) Set to Announce Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $4.75 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Down 4.0 %

NASDAQ:TSHA traded down $0.10 during mid-day trading on Wednesday, hitting $2.38. The company had a trading volume of 1,850,735 shares, compared to its average volume of 2,464,410. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $3.89. The business has a fifty day simple moving average of $2.66 and a 200-day simple moving average of $2.10. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $445.11 million, a price-to-earnings ratio of -3.55 and a beta of 0.37.

Wall Street Analysts Forecast Growth

TSHA has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, May 2nd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, April 30th. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Finally, Piper Sandler assumed coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an "overweight" rating and a $9.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has an average rating of "Buy" and an average price target of $6.88.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.